Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

NOVATO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's"). CHU d'Angers has received a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health, to fund the two-year, multi-center Phase II clinical trial in Huntington's patients. Under the terms of the agreement, Raptor will provide clinical supplies of DR Cysteamine for the trial.

In May 2008, the Office of Orphan Product Development at the U.S. Food and Drug Administration ("FDA") granted orphan drug designation to Raptor for cysteamine-based drugs, including DR Cysteamine, for the treatment of Huntington's.

Ted Daley, President of Raptor's Clinical Division, stated, "We look forward to collaborating with CHU d'Angers to evaluate DR Cysteamine in patients with Huntington's Disease. Our formation work with DR Cysteamine in conjunction with the CHU d'Angers studies in Huntington's fits our strategic plan to explore multiple potential indications for cysteamine and DR Cysteamine. Cysteamine has demonstrated neuroprotective effects in preclinical studies, and the planned Phase II study led by CHU d'Angers could confirm existing data regarding cysteamine's safety and potential efficacy in Huntington's."

Professor Dominique Bonneau, M.D., Ph.D. of CHU d'Angers, commented, "We are encouraged by the existing studies that indicate cysteamine's potential as a neuroprotectant for treating Huntington's, and we believe that Raptor's formulation could offer a better tolerated drug for this patient population. We are confident that this trial will enhance our
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Corporation (NYSE: SYK ) reported operating results for ... Third Quarter Highlights Net sales ... to $1,768 million Orthopaedic Implants sales increased 1.3% on ... Equipment sales increased 16.3% on a constant currency basis (16.1% ...
... Calif., Oct. 19 ThermoGenesis Corp. (Nasdaq: ... services that process and store adult stem cells, said ... agreement for its Res-Q™ 60 BMC (Res-Q) System with ... point-of-care cardiovascular therapies. Under the agreement, ...
Cached Medicine Technology:Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement 2ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement 3
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
(Date:12/24/2014)... 25, 2014 Epigenetics finds applications in ... including oncology, drug discovery, developmental biology, and research for ... one of the most widely used techniques for the ... the prevalence of cancer is rapidly growing worldwide. In ... million cancer deaths, and 32.6 million people living with ...
(Date:12/24/2014)... New studies reveal that women under the ... depression (March 6, 2014, JAMA Otolaryngology*). And although many people ... 50 percent according to recent polls) facing hearing loss head ... person feels and relates to the world. People who have ... made by way of:, , self-confidence , ...
(Date:12/24/2014)... 25, 2014 Today, Yunx.co.uk, a hot ... dresses and other special occasion outfits, unveils 65 ... are offered at discounted prices, up to 80% off. ... ladies with their fashionable designs, gorgeous looks and delicate ... The business is devoted to designing and offering high-quality ...
(Date:12/24/2014)... Thompson HealthDay Reporter TUESDAY, Dec. ... abstained from sex for one year will be allowed to donate ... would reverse a 31-year ban on donations from men who have ... Tuesday its intention to release a new draft guidance in early ... gay men. The FDA is changing its policy based on ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... Royal Philips Electronics (NYSE: ... portable at-home life-support ventilator. The highly versatile, lightweight ... in home ventilation from a recognized leader in respiratory ... noninvasive ventilation nearly 20 years ago. , , ...
... economic costs to Michigan citizens , ... introduced in the House of Representatives that would allow motorcyclists ... 4907, sponsored by Representative Richard LeBlanc (D-Westland), would make helmet ... a motorcycle. , , Every year, bikers ride ...
... School of Public Health, the South African National ... Service (NICD-NHLS), the U.S. Centers for Disease Control ... have discovered the new virus responsible for a ... South Africa in late 2008. It is ...
... recover faster from new procedure ... weight-loss procedure that involves sewing together the sides of ... gastric bypass surgery, suggest preliminary findings from a clinical ... reduction (TGVR), prevents the stomach from relaxing to accept ...
... Media Interviews , , NEW YORK, June 2 , ... Lisa DeAngelis, M.D., Chair of Neurology ... brain tumors, for developing a number of novel therapeutics and for running the ... the 2009 Gary Lichtenstein Humanitarian Award. , ...
... ... Updegraff Vision has launched an educational podcast site designed to allow prospective patients to view ... The podcasts provide an expert opinion on the various surgical vision correction options available ... ...
Cached Medicine News:Health News:Photos: Philips Expands Home Healthcare Commitment With Portable Life-Support Ventilator; Offers Ease of Use, Portability and Versatility for Patient 2Health News:Photos: Philips Expands Home Healthcare Commitment With Portable Life-Support Ventilator; Offers Ease of Use, Portability and Versatility for Patient 3Health News:Helmet Law Repeal Will Increase Health Care, Auto Insurance Costs 2Health News:New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia 2Health News:New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia 3Health News:Weight-Loss Surgery Simplified 2Health News:Voices Against Brain Cancer Hosts Event to Benefit Brain Cancer Research 2Health News:Updegraff Vision Launches Educational Blog/Podcast Site for LASIK and Cataract Patients 2
Length 6 (152 mm). Greenberg Retractor Kit is supplied with two primary bars. Primary bars attach to skull clamp....
TEW serrated micro-retractor blade set....
Micro-retractor arm 12"....
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...
Medicine Products: